Cross-Border Clinical Research: The Risks, Realities, and Regulatory Questions
- 0:00 Why Borders Still Matter
- 8:00 Jurisdiction Triggers And Scope
- 18:00 Frameworks That Diverge
Practical shifts you can apply this week
-
Identify Risk Points Early
Spot legal, operational, and ethical trouble before country plans and vendors turn it into rework.
-
Compare Jurisdiction Rules
See where oversight, data transfer, and participant protections align or quietly diverge.
-
Evaluate Remote Trial Obligations
Assess when decentralised activities add cross-border duties for consent, care, data, or shipping.
-
Diagnose Governance Gaps
Find weak handoffs between sponsors, CROs, vendors, and sites before accountability gets fuzzy.
-
Design Pre-Launch Review Process
Leave with a usable review flow for multinational protocols, vendors, and country choices.
What we'll cover
-
0:00
Why Borders Still Matter
Why remote workflows do not erase jurisdiction, and where teams underestimate cross-border risk.
-
8:00
Jurisdiction Triggers And Scope
How participant location, consent, product movement, and telehealth can trigger overlapping regimes.
-
18:00
Frameworks That Diverge
Where EU, US, UK, and APAC rules differ on ethics review, safety reporting, and product controls.
-
29:00
Data, Privacy, And Access
Transfers, localisation, wearable data, and why vendor architecture is rarely just an IT detail.
-
39:00
Operational Reality At Sites
Translation, home nursing, monitoring, and the handoffs where country-specific obligations get missed.
-
48:00
Ethics, Equity, Protection
Consent quality, payment disparities, post-trial access, and digital inclusion across countries.
-
55:00
Pre-Launch Framework And Close
A practical review checklist, recap, and invitation to test one active study against the framework this week.
Questions people ask before registering
-
It is built for working professionals involved in multinational studies: clinical operations, legal, privacy, quality, regulatory, and vendor oversight teams. If you touch country planning or study governance, it will be useful.
-
No. The session is designed for practitioners, not specialists only. We explain the regulatory questions in plain language and tie them to concrete study decisions.
-
Yes, a replay will be available after the session. Live attendance is still worth it if you want to stay for the closing discussion and Q&A.
-
Practical. The webinar uses real cross-border examples and ends with a pre-launch review framework you can apply to an active or planned study.
-
If certificates are being offered for this session, details are usually shared during registration or in the follow-up email. If that matters for your records, check the event page before attending.